Impact of Digoxin on Mortality in Patients With Atrial Fibrillation Stratified by Heart Failure: Findings From Gulf Survey of Atrial Fibrillation Events in the Middle East

Affiliations

05 January 2016

-

doi: 10.1177/1074248415603505


Abstract

Objective: The use of digoxin in patients having atrial fibrillation (AF) with or without heart failure (HF) is not without controversy. The aim of this study was to examine the impact of digoxin therapy on mortality stratified by HF.

Methods: Gulf Survey of Atrial Fibrillation Events was a prospective, multinational, observational registry of consecutive patients with AF recruited from the emergency department of 23 hospitals in 6 countries in the Middle East. Patients were recruited between October 2009 and June 2010 and followed up for 1 year after enrollment. Analyses were performed using univariate and multivariate statistical techniques.

Results: The study included a total of 1962 patients with AF, with an overall mean age of 56 ± 16 years, and 52% (n = 1026) were males. At hospital discharge, digoxin was prescribed in 36% (n = 709) of the patients, whereas HF was present in 27% (n = 528) of the cohort. A total of 225 (12.1%) patients died during the 12-month follow-up period after discharge (5.3% [n = 104] were lost to follow-up). Patients with HF were consistently associated with higher mortality at 1 month (5.1% vs 2.1%; P < .001), 6 months (17.2% vs 5.0%; P < 0.001), and 12 months (24.3% vs 7.6%; P < .001) when compared to those without HF. When stratified by HF, digoxin therapy was associated with significantly higher mortality in those without HF at 6 months (8.7% vs 3.7%; adjusted odds ratio (aOR), 5.07; P < .001) and 12 months (12.3% vs 6.0%; aOR, 4.22; P < .001) but not in those with HF (6 months: 18.6% vs 14.7%; aOR, 1.62; P = .177 and 12 months: 25.4% vs 22.4%; aOR, 1.37; P = .317).

Conclusions: In patients with AF and HF, digoxin did not offer any survival advantages. However, in those without HF, digoxin therapy was, in fact, associated with significantly higher long-term mortality.

Keywords: atrial fibrillation; digoxin; heart failure; middle east; mortality.


Similar articles

Digoxin and mortality in atrial fibrillation: a prospective cohort study.

Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H; RIKS-HIA group.Eur J Clin Pharmacol. 2007 Oct;63(10):959-71. doi: 10.1007/s00228-007-0346-9. Epub 2007 Aug 8.PMID: 17684738

Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus without heart failure.

Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Behlouli H, Pilote L.Am J Cardiol. 2014 Aug 1;114(3):401-6. doi: 10.1016/j.amjcard.2014.05.013. Epub 2014 May 16.PMID: 24950677 Clinical Trial.

Mortality in heart failure with atrial fibrillation: Role of digoxin and diuretics.

Gonzalez-Loyola F, Abellana R, Verdú-Rotellar JM, Bustamante Rangel A, Clua-Espuny JL, Muñoz MA.Eur J Clin Invest. 2018 Nov;48(11):e13014. doi: 10.1111/eci.13014. Epub 2018 Aug 23.PMID: 30091171

Is foxglove effective in heart failure?

Chaggar PS, Shaw SM, Williams SG.Cardiovasc Ther. 2015 Aug;33(4):236-41. doi: 10.1111/1755-5922.12130.PMID: 25925484 Review.

Digoxin - time to take the gloves off?

Eade E, Cooper R, Mitchell AR.Int J Cardiol. 2013 Apr 15;164(3):365-7. doi: 10.1016/j.ijcard.2011.07.034. Epub 2011 Jul 31.PMID: 21807421 Review.


Cited by

Utilization of Digoxin among Hospitalized Older Patients with Heart Failure and Atrial Fibrillation in Thailand: Prevalence, Associated Factors, and Clinical Outcomes.

Singkham N, Wongsalap Y, Poolpun D, Phetnoo S, Somkhon C.Ann Geriatr Med Res. 2021 Dec;25(4):260-268. doi: 10.4235/agmr.21.0098. Epub 2021 Dec 16.PMID: 34958732 Free PMC article.

Effect of Digoxin Therapy on Mortality in Patients With Atrial Fibrillation: An Updated Meta-Analysis.

Wang X, Luo Y, Xu D, Zhao K.Front Cardiovasc Med. 2021 Oct 1;8:731135. doi: 10.3389/fcvm.2021.731135. eCollection 2021.PMID: 34660731 Free PMC article.

Digoxin in Atrial Fibrillation: An Old Topic Revisited.

Ferrari F, Santander IRMF, Stein R.Curr Cardiol Rev. 2020;16(2):141-146. doi: 10.2174/1573403X15666190618110941.PMID: 31237216 Free PMC article. Review.

Prevalence and predictors of digoxin utilization among heart failure patients with reduced ejection fraction in Qatar.

Rahhal AA, Awaisu A, Tawengi KM, AbuYousef S, Mekideche L.Int J Clin Pharm. 2017 Oct;39(5):1070-1083. doi: 10.1007/s11096-017-0526-3. Epub 2017 Aug 19.PMID: 28823072

Clinical characteristics and prognostic impact of atrial fibrillation in patients with chronic heart failure.

Gigli L, Ameri P, Secco G, De Blasi G, Miceli R, Lorenzoni A, Torre F, Chiarella F, Brunelli C, Canepa M.World J Cardiol. 2016 Nov 26;8(11):647-656. doi: 10.4330/wjc.v8.i11.647.PMID: 27957251 Free PMC article.


KMEL References